Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05233722 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

mTOR as Mediator of Insulin Sensitivity Study

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Dec 2023 to Jun 2029v4
  2. Primary completion date: Dec 2022 to Dec 2023v3
  3. Interventions: Exercise (Biological), Insulin infusion (Procedure), Placebo (Drug), Rapamycin (Drug) to Exercise (Other), Insulin infusion (Procedure), Placebo (Drug), Rapamycin (Drug)
    • Secondary endpoints: details revised at 2 of 2 entries
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study investigates the role of mTOR in mediating enhancement of muscle insulin sensitivity following a single bout of exercise. This will be investigated in young healthy male subjects by administering the pharmacological mTOR inhibitor Rapamycin in a crossover blinded experimental setup known to enhance muscle insulin sensitivity following one-legged knee-extensor exercise.
Trial Details
NCT Number NCT05233722
Lead Sponsor University of Copenhagen
Collaborators: Danish Diabetes Academy
Conditions
(from sponsor)		 Insulin Sensitivity
Related terms Insulin Resistance, Motor Activity
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov